Articles tagged with “pharmaceutical-r-d”

Examine how fine-tuning foundation models and LLMs improves pharmaceutical R&D and drug discovery. Review Insilico's MMAI Gym methodology and AI benchmarks.

Guide to structuring a board-ready business case for enterprise AI in pharma. Review investment planning, ROI metrics, implementation strategies, and use cases.

Examine 2026 AI infrastructure investments in pharmaceutical R&D. This report details the Lilly-NVIDIA lab, Earendil funding, and GPU compute deployments.

Compare ELN, LIMS, and SDMS for pharmaceutical labs. This 2026 guide explains architectural differences, features, compliance, and specific R&D use cases.

Examine how 15 biotech startups utilize artificial intelligence to accelerate pharmaceutical R&D, drug discovery, and clinical trials. Read the full analysis.

Review 10 essential AI tools for pharmaceutical R&D in 2026. This report details platforms for protein structure, generative design, and clinical modeling.

Analyze the build vs buy AI decision in pharma. Compare costs, risks, and time-to-value for R&D and commercial teams to guide strategic investment.

Learn how to measure AI ROI in drug discovery beyond cost and time savings. Updated for 2026 with 173+ AI clinical programs, Insilico's Phase IIa results, Recursion-Exscientia merger, and new FDA guidance. Key metrics for scientific outcomes, pipeline productivity, and commercial value.

Learn how open source software like R and Python is changing pharma R&D. From Novo Nordisk's first R-based FDA submission to AlphaFold 3's open-sourcing, we analyze the accelerating shift from proprietary systems to collaborative drug discovery models.

An in-depth analysis of Merck's GPTeal platform and expanding AI strategy. Covers the KERMT drug discovery model, Mayo Clinic partnership, CSR automation results, and enterprise-scale LLM deployment across pharma R&D.